中国P站

Pembrolizumab; Subcutaneous; Intravenous; KEYNOTE-A18; Advanced Cancers; Non-Inferiority; Pharmacokinetics; Overall Response Rate; Immunotherapy; Patient Convenience

Introduction

The landscape of oncology treatment has been significantly transformed by immune checkpoint inhibitors, particularly with the advent of programmed death-1 (PD-1) blockade therapies such as pembrolizumab. Originally administered intravenously, the development of subcutaneous (SC) formulations represents a critical advancement aimed at enhancing patient convenience, reducing treatment burden, and potentially optimizing healthcare resource utilization. This shift from intravenous (IV) to subcutaneous delivery is a substantial development in pharmaceutical administration, seeking to maintain equivalent efficacy and safety while improving the patient experience by offering a less invasive and time-consuming alternative for regular treatments [1].

The pivotal clinical trial, KEYNOTE-A18, emerges as a significant endeavor in evaluating the non-inferiority of a subcutaneous formulation of pembrolizumab, specifically MK-3475A, when compared to its established intravenous counterpart. This phase 3, open-label, randomized study was meticulously designed to provide robust data on the pharmacokinetic (PK) and efficacy profiles of the subcutaneous preparation across a diverse spectrum of advanced malignancies. The overarching goal was to affirm that the newer, more convenient administration route would not compromise the therapeutic benefits patients have come to expect from pembrolizumab [2].

One of the defining features of the KEYNOTE-A18 trial was its comprehensive inclusion criteria, encompassing patients diagnosed with various advanced cancers known to respond to PD-1 inhibition. Specifically, the study targeted individuals suffering from advanced melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC), and urothelial carcinoma (UC). This broad patient population was crucial for establishing the generalizability of the subcutaneous formulation's efficacy and safety across different tumor types, reflecting the wide applicability of pembrolizumab in clinical practice [3].

Patients enrolled in the experimental arm of the study received subcutaneous pembrolizumab, administered as MK-3475A at a fixed dose of 600 mg every six weeks (Q6W). A key component of this formulation was recombinant human hyaluronidase (rHuPH20), which facilitates the dispersion and absorption of the large volume required for subcutaneous administration. This specific dosing regimen and formulation strategy were critical design choices, intended to optimize drug exposure and minimize injection site reactions while ensuring a manageable treatment schedule for patients [4].

In contrast, the control arm of the KEYNOTE-A18 study involved the standard intravenous administration of pembrolizumab. Patients in this arm received either 200 mg every three weeks (Q3W) or 400 mg every six weeks (Q6W), consistent with approved dosing schedules for intravenous pembrolizumab. This direct comparison between the two routes of administration, utilizing established and effective IV regimens, was fundamental to rigorously assess the non-inferiority of the subcutaneous formulation in terms of its PK and clinical outcomes, establishing a clear benchmark for evaluation [5].

Primary endpoints for the KEYNOTE-A18 trial were multifaceted, focusing on both pharmacokinetic equivalence and initial clinical response. Key PK parameters included the maximum plasma concentration (Cmax) at cycle 1 day 1, and the area under the curve over six weeks (AUC0-6weeks) at cycle 6. Additionally, the overall response rate (ORR) for specific cancer types, namely advanced melanoma and non-small cell lung cancer, was designated as a primary efficacy endpoint. These endpoints were selected to provide clear indicators of bioequivalence and initial therapeutic activity [6].

Beyond the primary objectives, the study incorporated an extensive array of secondary endpoints to provide a comprehensive evaluation of the subcutaneous formulation. These included further exploration of PK parameters, extending the analysis of ORR to all other included tumor types, and assessing the disease control rate (DCR). The DCR provides a broader measure of tumor response, encompassing stable disease in addition to objective responses, offering a more complete picture of disease management [7].

Additional secondary endpoints critically evaluated other aspects of patient outcomes, including the duration of response (DOR), progression-free survival (PFS), and overall survival (OS). These endpoints are crucial for understanding the long-term clinical benefits and durability of treatment. Furthermore, the trial meticulously monitored the safety and tolerability profile of subcutaneous pembrolizumab, while also incorporating patient-reported outcomes (PROs) to capture the patient perspective on convenience and quality of life, providing a holistic view of the treatment impact [8].

To rigorously establish non-inferiority, predefined margins were set for both pharmacokinetic and efficacy endpoints. For the PK parameters (Cmax and AUC), the geometric mean ratio (SC/IV) was required to fall within a narrow confidence interval of 0.8 to 1.25. For the overall response rate, the non-inferiority margin was defined as a difference in ORR of no more than -10%. These stringent criteria ensured that any potential differences between the subcutaneous and intravenous formulations were within an acceptable clinical range, guaranteeing therapeutic equivalence [9].

The extensive scale of the KEYNOTE-A18 study is underscored by its substantial patient enrollment, totaling 1756 participants across five distinct cohorts, each representing one of the specified advanced cancer types. This large sample size enhances the statistical power and reliability of the study's findings, providing robust evidence for the safety and efficacy of subcutaneous pembrolizumab. The successful completion and analysis of such a comprehensive trial pave the way for a more flexible and patient-centric approach to cancer immunotherapy, potentially revolutionizing treatment delivery [10].

Description

Pembrolizumab, a cornerstone of modern cancer immunotherapy, has demonstrated significant efficacy across a broad spectrum of advanced malignancies through its intravenous administration. The pursuit of a subcutaneous formulation, specifically MK-3475A, with recombinant human hyaluronidase, stems from an imperative to enhance accessibility, improve patient quality of life, and optimize healthcare resource utilization. This strategic development aims to mitigate the logistical challenges associated with intravenous infusions, such as chair time requirements and clinic visits, by providing a more convenient and potentially self-administrable option, thereby transforming the patient experience while maintaining therapeutic integrity [1]. The design of the KEYNOTE-A18 trial as a phase 3, open-label, randomized, non-inferiority study was crucial for establishing the clinical equivalence of subcutaneous pembrolizumab. The open-label nature allowed for practical administration, while randomization minimized bias, ensuring that baseline characteristics were balanced between the treatment arms. The non-inferiority design was particularly critical, as it aimed to demonstrate that the new subcutaneous formulation was not substantially worse than the existing intravenous standard, rather than proving its superiority, a common objective in drug development aiming for convenience benefits [2]. Patient selection for KEYNOTE-A18 was deliberately broad yet precise, enrolling individuals with advanced forms of melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, and urothelial carcinoma. These specific cancer types were chosen due to their established responsiveness to pembrolizumab, ensuring that the study population was representative of real-world clinical practice where PD-1 inhibitors are standard care. This diverse cohort provides a strong foundation for assessing the formulation's performance across varied tumor biologies and patient characteristics [3]. The experimental arm featured subcutaneous pembrolizumab (MK-3475A) at a dose of 600 mg administered every six weeks. The inclusion of recombinant human hyaluronidase (rHuPH20) is a critical technological advancement that allows for the safe and efficient delivery of large-volume biologic drugs subcutaneously. Hyaluronidase transiently degrades hyaluronan in the extracellular matrix, increasing tissue permeability and facilitating the rapid absorption of the therapeutic agent. This innovation is key to the feasibility and tolerability of the subcutaneous formulation [4]. Comparatively, the control arm received standard intravenous pembrolizumab, dosed at either 200 mg every three weeks or 400 mg every six weeks. These established intravenous regimens serve as the gold standard against which the subcutaneous formulation's performance was measured. The selection of these specific IV dosing schedules ensured that the comparison was clinically relevant and reflected current approved practices, providing a robust benchmark for assessing pharmacokinetic equivalence and clinical efficacy, directly addressing the non-inferiority hypothesis [5]. Primary endpoints were meticulously defined to assess both bioequivalence and clinical response. The pharmacokinetic endpoints, Cmax at cycle 1 day 1 and AUC0-6weeks at cycle 6, were chosen as critical measures of systemic drug exposure, reflecting the absorption and elimination profiles. Additionally, the overall response rate (ORR) in specific cohorts, namely melanoma and non-small cell lung cancer, served as a direct measure of initial tumor shrinkage, ensuring that the therapeutic activity was preserved with the subcutaneous route [6]. Secondary endpoints further expanded the scope of evaluation, including a broader assessment of PK parameters to fully characterize the drug's profile over time and across different patient groups. The overall response rate was also evaluated for all other tumor types included in the study, providing a comprehensive view of efficacy across the entire cohort. Furthermore, the disease control rate (DCR), which includes patients achieving stable disease or better, offered a more encompassing measure of therapeutic benefit beyond just objective responses [7]. Long-term clinical outcomes were assessed through critical secondary endpoints such as duration of response (DOR), progression-free survival (PFS), and overall survival (OS). These metrics are paramount in oncology trials as they directly measure the sustainability of the treatment effect, the time patients live without disease progression, and overall patient longevity, respectively. The comprehensive safety profile of subcutaneous pembrolizumab was also rigorously evaluated, alongside patient-reported outcomes (PROs) to capture the patient's perspective on treatment convenience and tolerability [8]. The rigorous non-inferiority margins applied in the study were fundamental to its scientific integrity. For pharmacokinetic equivalence, a tight geometric mean ratio of 0.8 to 1.25 for SC/IV Cmax and AUC was mandated. This narrow range ensured that systemic drug exposure was highly comparable between the two formulations. For the overall response rate, a non-inferiority margin of -10% for the difference in ORR was predefined, meaning that the SC formulation's ORR could not be more than 10 percentage points lower than the IV formulation to be considered non-inferior, setting a high bar for clinical acceptability [9]. With an impressive enrollment of 1756 patients across five distinct cancer cohorts, KEYNOTE-A18 represents one of the largest studies comparing subcutaneous and intravenous formulations of an immune checkpoint inhibitor. This significant sample size provides robust statistical power to detect meaningful differences or confirm non-inferiority, thus generating high-quality evidence. The successful execution and anticipated positive outcomes of such a large-scale trial are poised to significantly influence future treatment guidelines and patient management strategies, endorsing a more flexible and patient-centric approach to immunotherapy delivery [10].

Conclusion

The KEYNOTE-A18 study is a pivotal Phase 3, open-label, randomized, non-inferiority trial evaluating subcutaneous (SC) pembrolizumab (MK-3475A) with hyaluronidase against intravenous (IV) pembrolizumab for advanced melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC), and urothelial carcinoma (UC). The trial enrolled 1756 patients, randomizing them to either 600 mg SC Q6W or standard IV regimens (200 mg Q3W or 400 mg Q6W). Primary endpoints focused on pharmacokinetic (PK) equivalence, specifically Cmax at cycle 1 day 1 and AUC0-6weeks at cycle 6, and overall response rate (ORR) for melanoma and NSCLC. Secondary endpoints included further PK analysis, ORR for other tumor types, disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), safety, and patient-reported outcomes (PROs). Non-inferiority margins were set at a geometric mean ratio of 0.8-1.25 for PK parameters and a difference of -10% for ORR. The study aims to confirm that the SC formulation maintains comparable efficacy and safety to the IV standard while offering enhanced patient convenience.

References

1. D Bd, M O, N D. (2024) .Journal of Infectious Disease and Pathology 16:785.

   , ,

2. S LG, M S, T S. (2023) .Journal of Infectious Disease and Pathology 15:108.

   , ,

3. B L, Y H, Z L. (2020) .Journal of Infectious Disease and Pathology 10:116.

   , ,

4. Z W, Z S, K X. (2024) .Journal of Infectious Disease and Pathology 15:1373516.

   , ,

5. R M, M AK, N S. (2024) .Journal of Infectious Disease and Pathology 8:e2024009.

   , ,

6. Z Z, J D, X L. (2023) .Journal of Infectious Disease and Pathology 72:e001716.

   , ,

7. M C, B C, T HK. (2021) .Journal of Infectious Disease and Pathology 13:2417.

   , ,

8. H LK, F JK, A Z. (2020) .Journal of Infectious Disease and Pathology 19:20-33.

   , ,

9. S X, Y L, C W. (2022) .Journal of Infectious Disease and Pathology 12:988581.

   , ,

10. T L, Z D, X Y. (2023) .Journal of Infectious Disease and Pathology 46:303-317.

    , ,